Condition (MeSH)
Hepatic Veno-Occlusive Disease
ClinicalTrials.gov lists 23 trials for Hepatic Veno-Occlusive Disease or a narrower condition beneath it. Jazz Pharmaceuticals has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
23 of the 23 trials are tagged with Hepatic Veno-Occlusive Disease itself; the rest are tagged with a narrower condition beneath it.
When did Hepatic Veno-Occlusive Disease trials start? (17)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Expanded access
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 2 |
| 2023 | 1 |
| 2021 | 2 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 2 |
| 2015 | 3 |
Showing 10 of 17 earlier years.
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hepatic Veno-Occlusive Disease trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 5 |
| Phase 2/3 | 1 |
| Phase 3 | 3 |
| Phase 4 | 1 |
| Not applicable | 6 |
| Observational | 6 |
| Expanded access | 1 |
How many Hepatic Veno-Occlusive Disease trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 2 |
| Completed | 12 |
| Terminated | 1 |
| Withdrawn | 1 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hepatic Veno-Occlusive Disease trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Jazz Pharmaceuticals | 4 |
| European Society for Blood and Marrow Transplantation | 1 |
| Hospital Authority, Hong Kong | 1 |
Which drugs are being tested for Hepatic Veno-Occlusive Disease? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Defibrotide | 7 |
Interventions as named in the registry (4)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| N Acetylcysteine | 1 |
| Contrast Enhanced Ultrasound (CEUS) | 1 |
| Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU | 1 |
| Glutamin | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hepatic Veno-Occlusive Disease trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Multi-organ failure | 154 | 2 |
| Respiratory failure | 103 | 3 |
| Venoocclusive liver disease | 103 | 3 |
| Hypotension | 65 | 3 |
| Pulmonary haemorrhage | 58 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Hepatic Veno-Occlusive Disease? (83)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
Showing 5 of 83 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Hepatic veno-occlusive disease | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Hepatic veno-occlusive disease | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Hepatic veno-occlusive disease | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Hepatic veno-occlusive disease | 890 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Hepatic veno-occlusive disease | 890 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.